Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient preferences for EGFR mutation-targeted therapies in non-small cell lung cancer, with a focus on Exon 20 insertions.

Lung cancer (Amsterdam, Netherlands)·2025
Same author

Brief Report: Phase II Clinical Trial of Atezolizumab in Advanced Nonsmall Cell Lung Cancer Patients Previously Treated With PD-1-Directed Therapy.

Clinical lung cancer·2024
Same author

The management of acute complete ruptures of the ulnar collateral ligament of the thumb.

Bone & joint open·2024
Same author

Sinonasal squamous cell carcinoma in the United States: Temporal and geographic patterns associated with HPV testing and positivity.

Oral oncology·2024
Same author

Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2023
Same author

A rare case of ductal variant multilocular prostatic cystadenocarcinoma invading the rectum.

Urology case reports·2023
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
Same journal

Current Understanding of CHIP's Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature.

Current oncology reports·2026
Same journal

The Role of EZH2 ın Malıgnant Pleural Mesothelıoma and Beyond: Current Practıce and Future Perspectıves.

Current oncology reports·2026
See all related articles

Related Experiment Video

Updated: May 22, 2026

Formation of Human Thymus Organoids in Three-Dimensional Fibrin Hydrogels
03:31

Formation of Human Thymus Organoids in Three-Dimensional Fibrin Hydrogels

Published on: October 4, 2024

Thymic neoplasms: a clinical update.

Mark Mikhail1, Yasmin Mekhail, Tarek Mekhail

  • 1Imperial College London School of Medicine, London, UK. mark.mikhail07@imperial.ac.uk

Current Oncology Reports
|May 29, 2012
PubMed
Summary
This summary is machine-generated.

Thymoma, a mediastinal neoplasm, often presents with myasthenia gravis. Surgical resection offers the best prognosis, with radiotherapy and chemotherapy used for advanced or invasive thymoma.

More Related Videos

Isolation and Transplantation of Different Aged Murine Thymic Grafts.
05:47

Isolation and Transplantation of Different Aged Murine Thymic Grafts.

Published on: May 13, 2015

Isolation, Identification, and Purification of Murine Thymic Epithelial Cells
07:20

Isolation, Identification, and Purification of Murine Thymic Epithelial Cells

Published on: August 8, 2014

Related Experiment Videos

Last Updated: May 22, 2026

Formation of Human Thymus Organoids in Three-Dimensional Fibrin Hydrogels
03:31

Formation of Human Thymus Organoids in Three-Dimensional Fibrin Hydrogels

Published on: October 4, 2024

Isolation and Transplantation of Different Aged Murine Thymic Grafts.
05:47

Isolation and Transplantation of Different Aged Murine Thymic Grafts.

Published on: May 13, 2015

Isolation, Identification, and Purification of Murine Thymic Epithelial Cells
07:20

Isolation, Identification, and Purification of Murine Thymic Epithelial Cells

Published on: August 8, 2014

Area of Science:

  • Oncology
  • Thoracic Surgery
  • Pathology

Background:

  • Thymoma is a rare tumor originating in the anterior mediastinum.
  • It is frequently linked to paraneoplastic syndromes, notably myasthenia gravis, with one-third of cases diagnosed during its evaluation.
  • Current classification systems have limitations in predicting thymoma's prognosis and disease progression.

Purpose of the Study:

  • To review the clinical behavior, prognostic indicators, and treatment strategies for thymoma.
  • To emphasize the importance of staging in predicting clinical outcomes.
  • To outline current therapeutic recommendations for thymoma management.

Main Methods:

  • Review of existing literature on thymoma diagnosis, staging, and treatment.
  • Analysis of prognostic factors, including tumor encapsulation and surgical resection.
  • Evaluation of the role of adjuvant radiotherapy and chemotherapy.

Main Results:

  • Encapsulated thymomas that undergo complete surgical resection demonstrate the most favorable prognosis.
  • Adjuvant radiotherapy is indicated for incompletely excised and invasive thymomas.
  • Anthracycline-based chemotherapy is the most effective systemic treatment for neoadjuvant, adjuvant, and palliative settings.

Conclusions:

  • Thymoma staging is crucial for predicting clinical behavior and guiding treatment decisions.
  • Multimodality treatment, including surgery, radiotherapy, and chemotherapy, is essential for managing thymoma effectively.
  • Optimal management strategies depend on tumor stage, resectability, and invasiveness.